Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
Earnings Data
Report Date
May 05, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
<0.01Last Year’s EPS
0Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a constructive operational and commercial story: record FY2025 revenue, robust clinical and NGS growth, new product launches (RADAR ST, PanTracer Pro), strong customer satisfaction (NPS 79), and a confident 2026 financial guide with meaningful adjusted EBITDA growth and a goal to achieve free cash flow positivity. Offsetting these positives are notable headwinds: a significant decline in nonclinical revenue, near-term margin pressure from the Pathline acquisition and launch costs, intentional volume rationalization that temporarily lowered volumes, and timing uncertainty around MolDX reimbursements for key liquid offerings. Management articulated clear strategies to prioritize higher-value testing, expand the salesforce, and deliver LIMS-driven efficiency gains over the coming years.Company Guidance
Record Revenue and Full-Year Growth
Total revenue for FY2025 was $727.0M, representing 10% growth versus FY2024; Q4 total revenue was $190.0M, up 11% year-over-year.
Clinical Business Strength
Total clinical revenue grew 15% for the full year (13% excluding Pathline); Q4 clinical revenue increased 16% year-over-year, driven by volume and AUP gains.
NGS Outperformance
NGS revenue grew 23% year-over-year in Q4 and accounted for roughly one-third of total clinical revenue; five NGS products launched in 2023 contributed 23% of clinical revenue in Q4.
Improved Profitability Metrics
Q4 adjusted gross profit improved by $5.8M (7% YoY) and adjusted EBITDA was $13.4M, up 10% YoY; FY2025 adjusted EBITDA was $43.4M, a 9% improvement versus prior year.
Operational Momentum and Volume Trends
Public test volumes increased 11% in Q4; same-store revenue (excluding Pathline) was $170.0M in Q4, up 14% driven by a 6% increase in volumes and 7% AUP growth.
Strong Customer Satisfaction and Commercial Execution
Net Promoter Score of 79 and continued improvement in 2025; 14% growth in the number of pathologists/oncologists ordering five or more tests and an estimated ~40% of active pathologists/oncologists ordering five or more tests in 2025.
Strategic Product Launches and Reimbursement Wins
RADAR ST bridging study showed 97% concordance with RADAR 1.0 and secured MolDX reimbursement for HPV-negative head & neck and a subset of breast cancers; full clinical launch targeted by end of the month. PanTracer tissue volumes nearly doubled YoY (2024->2025) and PanTracer Pro was launched.
2026 Guidance and Financial Targets
2026 revenue guidance of $793M–$801M (midpoint ~ $797M) implying ~10% growth; adjusted EBITDA guidance $55M–$57M, representing ~27%–31% YoY growth; company aims to be free cash flow positive in 2026.
Balance Sheet and Cash Position
Ended Q4 with $160.0M of total cash and positive operating cash flow of $1.0M in Q4 and $5.0M for FY2025, with free cash flow improving over 35% versus 2024.
Commercial Capacity Expansion
Invested in salesforce: added 35 oncology sales specialists in late 2024/2025 and plans to add >25 oncology sales specialists by Q3 2026 to support RADAR ST and PanTracer commercialization.
NEO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NEO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 17, 2026 | $11.38 | $11.44 | +0.53% |
Oct 28, 2025 | $10.16 | $9.92 | -2.36% |
Jul 29, 2025 | $6.46 | $5.25 | -18.73% |
Apr 29, 2025 | $9.97 | $6.58 | -34.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NeoGenomics (NEO) report earnings?
NeoGenomics (NEO) is schdueled to report earning on May 05, 2026, TBA (Confirmed).
What is NeoGenomics (NEO) earnings time?
NeoGenomics (NEO) earnings time is at May 05, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NEO EPS forecast?
NEO EPS forecast for the fiscal quarter 2026 (Q1) is <0.01.
